Table 7 Adverse events
|  | Dapagliflozin group (n = 40) | Metformin group (n = 40) | P value |
|---|---|---|---|
Any adverse events | 6 (15.0) | 9 (22.5) | 0.57 |
Hypoglycemia | 1 (2.5) | 0 (0.0) | 1.00 |
Allergic rhinitis | 0 (0.0) | 1 (2.5) | 1.00 |
Dry mouth | 1 (2.5) | 0 (0.0) | 1.00 |
Esophageal varices hemorrhage | 1 (2.5)a | 0 (0.0) | 1.00 |
Frequent urination | 1 (2.5) | 0 (0.0) | 1.00 |
Upper respiratory tract infection | 0 (0.0) | 1 (2.5) | 1.00 |
Interstitial lung disease | 1 (2.5)a | 0 (0.0) | 1.00 |
Gastroesophageal reflux disease | 1 (2.5) | 0 (0.0) | 1.00 |
Wound | 1 (2.5) | 0 (0.0) | 1.00 |
Pharyngitis | 0 (0.0) | 1 (2.5) | 1.00 |
Dyslipidemia | 1 (2.5) | 0 (0.0) | 1.00 |
Decrease in appetite | 0 (0.0) | 1 (2.5) | 1.00 |
Alopecia areata | 0 (0.0) | 1 (2.5) | 1.00 |
Palpitation | 0 (0.0) | 1 (2.5) | 1.00 |
Cervical dysplasia | 0 (0.0) | 1 (2.5)a | 1.00 |
Lung cancer, stage 0 | 0 (0.0) | 1 (2.5)a | 1.00 |
Contusion | 0 (0.0) | 1 (2.5) | 1.00 |
Diarrhea | 0 (0.0) | 1 (2.5) | 1.00 |